Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.

Marie Beylot-BarryNina BookenCarsten WeishauptJulia ScarisbrickWende WuJan-Paul RosenMichael C Medley

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

In mogamulizumab-treated MF patients, ORR and PFS were seen to improve with increasing blood involvement, which led to improved TTNT. TTR was more predictable for mogamulizumab-treated MF patients with blood involvement, and skin response may take longer than previously reported in some patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis
patient reported outcomes
case report
wound healing